LAS VEGAS, Nov. 18, 2020
- Epidermolysis bullosa market's evaluation sees a steep surge in the market growth owing to the launch of pipeline therapies that are expected between 2021-24, elevated R&D, and an increase in the funding from international support organizations
LAS VEGAS, Nov. 18, 2020 /PRNewswire/ -- DelveInsight's 'Epidermolysis bullosa (EB) Market Insights' report offers a comprehensive and thorough description of the disease, its epidemiological trends, treatment landscape, and market trends, opportunities and constraints in the 7MM ( the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan) for the study period 2017-30.
Research Highlights from the Epidermolysis bullosa Market report:
To know how the trends will be impacting the market, click on the link to download the sample@ https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market
Epidermolysis bullosa is a group of heterogeneous congenital skin conditions that causes varying degrees of blisters. An error or mutation in the keratin or collagen gene that is at least a group of at least 18 genes encoding structural proteins, causes the condition. The condition is usually diagnosed in babies and children; however, this does not rule out the possibility of adults developing Epidermolysis bullosa.
The external appearance of the skin gives a clear indication of the condition, however, laboratory tests such as skin biopsy, genetic, and prenatal testing confirm its diagnosis. It is of several types, however, there are four major types of EB, depending on the location of the target proteins and level of the blisters: EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), and Kindler syndrome. Out of the total Epidermolysis bullosa prevalent cases estimated to be 41,509 in 2017, the majority of the cases were contributed by EBS followed by DEB and JEB.
Epidermolysis bullosa Market Report proffers 3-year historical as well as 11-year forecasted epidemiological analysis segmented into:
Epidermolysis bullosa Market Landscape
The present Epidermolysis bullosa treatment market is limited to palliative care. The primary goal of the available treatment regimen is to prevent blisters and manage wounds. Different treatments are used depending on the type of EB. Local treatment of the skin (and mucosa) is part of daily care. Vaseline or silicone-coated non-stick lattice-structured gauze dressings, for example, a Sofratulle dressing, as well as self-adherent bandages and tube bandages are good options for dressing skin defects. In addition to wound management, attention must also be paid to optimizing nutrition and dental health, minimizing deformity, ophthalmic complications, and genitourinary problems. To manage pain, OTC medications are prescribed. In the case of chronic pain, pain medications such as amitriptyline, gabapentin, or pregabalin may be prescribed. For severely-affected patients, long-acting opioids can be beneficial. Antihistamines, gabapentin, pregabalin, TCA, serotonin-norepinephrine uptake inhibitors (SNRIs), and other non-traditional antipruritic agents are considered for itch treatment.
There is neither EB-specific medication nor standard cure to address the underlying condition. Available medications are ineffective in reducing morbidity and mortality due to complications of the disease. The available medications are also known to cause side effects. Further, the presence of multiple wounds of varying duration and ability to heal makes the management of EB difficult and complex.
However, the present EB market scenario offers immense opportunities for pharmaceutical companies to exploit the market. The increasing attention towards the genetic, rare skin condition is anticipated to yield dramatic results in transforming the Epidermolysis bullosa market landscape. Several pharma companies in the Epidermolysis bullosa market are exploring novel therapeutics to transform the EB treatment landscape. Key pharma players, such as Fibrocell Technologies, Castle Creek Pharmaceuticals, RegeneRx, Amryt Pharma, Abeona Therapeutics, Krystal Biotech, Shionogi, among others, are developing therapies that are in different stages of clinical development for the treatment of EB. The launch of FCX-007 (Fibrocell Technologies), CCP-020 (Castle Creek Pharmaceuticals), RGN-137 (RegeneRx/Lenus Therapeutics), AP-101 (Amryt Pharma), EB-101 (Abeona Therapeutics), KB103 (Krystal Biotech), and S-005151 [Redasemtide] (Shionogi) is expected to drive the Epidermolysis bullosa drugs market during the forecasted period (2020–2030). The shifted focus towards strengthening the Epidermolysis bullosa pipeline is expected to bolster the development of novel and effective treatments without side effects. Furthermore, an increase in funds for R&D to augment understanding of epidermolysis bullosa shall drive the EB market growth in the next decade.
Epidermolysis bullosa Emerging Pipeline Therapies
Scope of the Report
Table of Contents
Executive Summary of Epidermolysis bullosa
Epidermolysis bullosa Market Overview at a Glance
Disease Background and Overview: Epidermolysis bullosa
Epidermolysis bullosa Case Reports
Epidermolysis bullosa Epidemiology and Patient Population
Country Wise-Epidemiology of Epidermolysis Bullosa
Epidermolysis bullosa Treatment and Management
Epidermolysis bullosa Unmet Needs
Epidermolysis bullosa Emerging Therapies
Failed Therapies for Epidermolysis bullosa (EB)
7MM Market Outlook
US Epidermolysis bullosa Market Outlook
EU5 Epidermolysis bullosa Market Outlook
Japan Epidermolysis bullosa Market Outlook
Epidermolysis bullosa Market Drivers
Epidermolysis bullosa Market Barriers
Epidermolysis bullosa Reimbursement and Market Access
Browse Detailed TOC, Tables, Figures, Emerging Drugs and Companies @ Epidermolysis bullosa market size
DelveInsight's "Dystrophic Epidermolysis bullosa - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Dystrophic Epidermolysis bullosa, historical and forecasted epidemiology as well as the Dystrophic Epidermolysis bullosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.